RB Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

RB Capital Management LLC increased its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 17.4% in the 2nd quarter, HoldingsChannel reports. The fund owned 6,391 shares of the biopharmaceutical company’s stock after purchasing an additional 945 shares during the quarter. RB Capital Management LLC’s holdings in Pfizer were worth $335,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Baltimore Washington Financial Advisors Inc. purchased a new position in Pfizer in the fourth quarter worth approximately $290,000. Rinkey Investments acquired a new position in Pfizer during the fourth quarter worth $32,000. Worth Asset Management LLC acquired a new position in Pfizer during the first quarter worth $29,000. Bivin & Associates Inc. acquired a new position in Pfizer during the fourth quarter worth $37,000. Finally, Stuart Chaussee & Associates Inc. lifted its stake in Pfizer by 108.3% during the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 325 shares in the last quarter. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. SVB Leerink decreased their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. UBS Group set a $59.00 price objective on Pfizer in a research note on Thursday, September 1st. Finally, Barclays set a $50.00 price objective on Pfizer in a research note on Thursday, September 1st. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $57.00.

Pfizer Stock Performance

Shares of PFE stock opened at $44.57 on Friday. The stock’s 50-day moving average is $48.40 and its two-hundred day moving average is $50.33. The firm has a market cap of $250.14 billion, a price-to-earnings ratio of 8.72, a PEG ratio of 0.54 and a beta of 0.70. Pfizer Inc. has a 1 year low of $40.94 and a 1 year high of $61.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The business’s quarterly revenue was up 46.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.07 earnings per share. Analysts predict that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.59%. Pfizer’s payout ratio is 31.31%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.